Bladder Cancer VL

Current and Emerging Therapies for Non-Muscle Invasive Bladder Cancer after BCG - Chris Wallis & Zach Klaassen

Details
For this Journal Club, Christopher Wallis, MD, and Zach Klasseen, MD discuss a recently published meta-analysis on treatment options for patients with non-muscle invasive bladder cancer unresponsive or refractory to BCG therapy. They provide context for this review and discuss the clinical relevance of managing the risk of recurrence in NMIBC. Biographies: Zachary Klaassen, MD, MSc, Urologic Oncol...

Phase III Nadofaragene Firadenovec for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Joshua J. Meeks

Details
In this discussion, Josh Meeks joins Alicia Morgans to review the new advances phase III Nadofaragene Firadenovec (Adstiladrin®) trial for BCG unresponsive non-muscle invasive bladder cancer patients. Dr. Meeks details the results of this recently presented trial data and why he believes this is the beginning of the next era in treating these patients. Biographies: Josh J. Meeks, MD, Ph.D., Assist...

The BCG Shortage - What To Do In This Setting - Joshua Meeks

Details
Alicia Morgans and Joshua Meeks discuss the current shortage of Bacille Calmette-Guérin (BCG) and how it is impacting clinicians' treatment decisions and ongoing clinical trials. Dr. Meeks shares his thoughts behind the shortage and provides his strategy for clinicians and teams to make the proper patient selection to use the available BCG effectively to cover as many patients as possible. Biograp...

Advancements in BCG Unresponsive Bladder Cancer: Highlights from the 2019 SUO Meeting - Joshua Meeks

Details
Alicia Morgans and Joshua Meeks discuss the recent advancements in treating Bacille Calmette-Guérin (BCG) unresponsive bladder cancer that came from the 2019 meeting of the Society of Urologic Oncology. They review the many promising clinical trials including some early data from the Phase III VICINIUM trial as well as a promising combination intravesical chemotherapy options for non-muscle-invasi...

A New Era In Systemic Therapies, Pembrolizumab for High Risk Non-Muscle Invasive BCG-Refractory Patients - Arjun Balar

Details
Arjun Balar and Alicia Morgans discuss the new era in systemic therapies in non-muscle invasive bladder cancer (NMIBC) focusing on the systemic checkpoint inhibitor, pembrolizumab that resulted in the US FDA approval of pembrolizumab for treatment in early bladder cancer. Historically being in the domain of urologic oncologists, Drs. Morgans and Balar discuss the importance of the medical oncologi...

Utilizing Change Management for Successful Implementation of Blue light cystoscopy (BLC™) - Rebecca Roe

Details
Rebecca Roe speaks to an interdisciplinary approach to implementation of Blue Light Cystoscopy (BLC™) in her community hospital center, giving a Clinical Education Program Coordinator's perspective. Her team engaged in the five management practices looking at ongoing communication and clinical training and measured things along the way, seeking feedback from every discipline that was utilized, whe...

Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy - Badrinath Konety

Details
Cxbladder diagnostic tests combine genomic information from urinary mRNA with phenotypic information to either rule out low-risk individuals or identify patients at a high risk of urothelial carcinoma (UC). In this video presentation, Badrinath Konety overviews this study which aimed to evaluate the performance of Cxbladder and urine cytology and Cxbladder's adjudication of atypical cytology and e...

Guided Imagery for Urologic Surgery - Sima Porten

Details
Sima Porten discusses her work on using guided imagery to decrease anxiety for patients prior to undergoing major urologic surgery. Patients were asked to listen to guided imagery tapes and MP3s at least once a day for the two weeks leading up to their surgery. Patients were given an anxiety survey before receiving the tape and also the day before surgery. Patients also used a text messaging app t...

Consensus Statement on Flexible Blue Light Cystoscopy (BLC™) with Cysview® - Yair Lotan

Details
Yair Lotan discusses the recently published consensus statement on flexible blue light cystoscopy (BLC™) with Cysview ® . His presentation is centered around the published consensus in Nature Reviews developed by multiple experts (authors) in bladder cancer. Yair discusses the role of blue light flexible cystoscopy with CYSVIEW in non-muscle invasive bladder cancer. The expert consensus group met...

Journal Club: The Evaluation of Cxbladder and Adjudication of Atypical Cytology - Sia Daneshmand

Details
Sia Daneshmand discusses a study published in European Urology which evaluated the atypical cytologies to evaluate the performance of Cxbladder diagnostic tests to either rule out low-risk individuals or identify patients at a high risk of urothelial carcinoma. Cxbladder diagnostic tests combine genomic information from urinary mRNA with phenotypic information. Biography: Siamak (Sia) Daneshmand,...